Lipoxin A4 in Gingival Crevicular Fluid Predicts Treatment Outcomes in Severe Periodontitis

Title: 'Examining the Role of Lipoxin A4 in Gingival Crevicular Fluid as a Predictor of Treatment Outcomes in Severe Periodontitis'

**Introduction:**Lipoxin A4 (LXA4) is a specialized pro-resolving mediator known to play a role in inflammation resolution. This study investigates the potential of LXA4 levels in gingival crevicular fluid (GCF) as a predictor of treatment outcomes in patients with severe periodontitis.

**Methods:**GCF samples were collected from 21 participants with severe periodontitis at baseline and 1, 3, and 6 months after scaling and root planing (SRP). LXA4 levels were measured, and correlations with clinical parameters like pocket depth and clinical attachment level were analyzed.

**Results:**LXA4 levels in GCF significantly increased following SRP but remained lower than levels observed in healthy individuals or those with gingivitis. Importantly, lower baseline LXA4 concentrations were associated with greater improvements in pocket depth and clinical attachment level at 6 months post-treatment. The improvements positively correlated with the increase of LXA4 post-treatment. Additionally, sites that became negative for periodontal pathogens Prevotella intermedia or Tannerella forsythia after SRP exhibited elevated LXA4 levels.

**Conclusion:**These findings suggest that LXA4 in GCF holds potential as a predictive biomarker for site-specific treatment response to SRP in severe periodontitis. This could aid clinicians in risk assessment and treatment planning. The application of LXA4 as a therapeutic agent in periodontitis may be particularly relevant after SRP has been performed.